"A biomedical programme for urban violence control in the U.S." (Peter Breggin and Ginger Ross Breggin). Changes:
An International Journal of Psychology and Psychotherapy 11, No. 1
(March) :59-71, 1993.
"Empathic Self-Transformation and Love in Individual and Family Therapy." The Humanistic Psychologist, 27:267-282, 1999.
"Lobotomies: An Alert." (letter) American Journal of Psychiatry 129:98-99, 1972.
"Neuropathology and Cognitive Dysfunction from ECT." Psychopharmacology Bulletin 22:476-479, 1986.
"Electroshock Therapy and Brain Damage: The Acute Organic Brain Syndrome as Treatment." Behavior and Brain Sciences 7:24-25, 1984.
"What Cost Leukotomy?" (letter) American Journal of Psychiatry 140:1101, 1983.
"Campaigns against racist federal programs by the Center for the Study of Psychiatry and Psychology." Journal of African American Men 1:No. 3, 3-22. Winter 1995/96.
"What Psychologists and Psychotherapists Need to Know About ADHD and Stimulants." Changes: An International Journal of Psychology and Psychotherapy, 18:13-23, Spring 2000.
International Journal of Risk & Safety in Medicine 22 (2010) 89-92.
Peter R. Breggin
Abstract: Electroconvulsive therapy (ECT) and the machines that deliver it have never been tested for safety and efficacy in order to receive approval from the FDA. The American Psychiatric Association and ECT advocates protested when the FDA took steps to classify the machines as posing “an unreasonable risk of illness or injury”, which would have required their testing before approval. Without requiring this testing, the FDA is now preparing to classify the treatment and the machines as safe. This article reviews evidence demonstrating that ECT is very harmful to the brain and mind, and concludes that the FDA should demand the usual testing, starting with animals, that is required before psychiatric treatments and machines are approved for marketing and use.
“TBI, PTSD, and psychiatric drugs. A perfect storm for causing abnormal mental states and aberrant behavior.” In Brock, H. and Else, R.C. (Eds). The Attorney’s Guide to Defending Veterans in Criminal Court. Minneapolis, MN: Veterans Defense Project. Chapter 10, pp. 251-264, 2014.
Peter R. Breggin, MD
Recent years have seen a marked increase in the prescription of psychiatric drugs to activity duty military personnel and to veterans. Until the Iraq and Afghanistan wars, soldiers were rarely if ever sent into combat while taking psychiatric drugs, but now it is commonplace, and may occur in 20% or considerably more of combat troops. Nearly all soldiers returning from combat with psychiatric diagnoses will be placed on multiple psychiatric drugs and maintained on them during treatment at the VA.